With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Age-related macular degeneration (AMD) is a leading cause of irreversible severe vision loss and blindness in patients 50 and older. Neovascular AMD is responsible for 80% of cases of severe vision loss due to AMD.
Unprecedented visual gains were obtained with monthly intravitreal ranibizumab in the pivotal randomized clinical trials and led to a paradigm shift in the treatment of neovascular AMD. According to a study, long-term treat-and-extend anti-VEGF therapy maintains vision in some patients, even after 8 years and more than 50 injections. For the 71 patients with neovascular age-related macular degeneration who had received at least 50…
